Profile data is unavailable for this security.
About the company
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
- Revenue in USD (TTM)32.15m
- Net income in USD-39.92m
- Incorporated2005
- Employees73.00
- LocationAssembly Biosciences IncTwo Tower Place, 7Th FloorSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (212) 554-4388
- Fax+1 (646) 706-5101
- Websitehttps://www.assemblybio.com/